

CLAIMS

We claim:

1. A method for administering a lipopeptide antibiotic, comprising the step of administering to a patient in need thereof a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity.  
5
2. The method according to claim 1, wherein the lipopeptide antibiotic is administered once every 24 hours to once weekly.
- 10 3. The method according to claim 2, wherein the lipopeptide antibiotic is administered once every 24 hours, 48 hours, 72 hours or 96 hours
4. The method according to claim 1, wherein the lipopeptide antibiotic is selected from the group consisting of daptomycin, a daptomycin derivative, A54145 and a A54145 derivative.
- 15 5. The method according to claim 4, wherein the lipopeptide antibiotic is daptomycin.
6. A method for administering daptomycin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of daptomycin in a dose of 3 to 75 mg/kg of daptomycin, wherein the daptomycin is  
20 administered once every 24 hours to once weekly.
7. The method according to claim 6, wherein the dose is 3 to 12 mg/kg.

8. The method according to claim 7, wherein the dose is 3, 4, 5, 6,  
7, 8, 9, 10, 11 or 12 mg/kg.

9. The method according to claim 6, wherein the dose is 10 to 25  
mg/kg.

5 10. The method according to claim 9, wherein the dose is 10, 11,  
12, 13, 14, 15, 16, 20 or 25 mg/kg.

11. The method according to either of claim 1 or claim 6, wherein  
an antibiotic other than a lipopeptide antibiotic is co-administered with the  
lipopeptide antibiotic.

10 12. The method according to claim 11 wherein said lipopeptide  
antibiotic is daptomycin.

13. The method according to claim 11, wherein said antibiotic is  
selected from the group consisting of penicillins and related drugs, carbapenems,  
cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin,  
15 mupirocin, chloramphenicol, thiampenicol, fusidate sodium, lincomycin,  
clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin,  
tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents,  
sulfonamides, trimethoprim and its combinations, pyrimethamine, synthetic  
antibacterials, nitrofurans, methenamine mandelate, methenamine hippurate,  
20 nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide,  
para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide,  
prothionamide, thiacetazone and viomycin.

100354-0200

14. The method according to claim 11, wherein said antibiotic is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin and teicoplanin.

15. The method according to claim 11, wherein said administering is  
5 via oral, subcutaneous or intravenous administration.

16. A method for administering daptomycin, comprising the step of administering to a patient or animal in need thereof a therapeutically effective amount of daptomycin at a dose of 3 to 75 mg/kg of daptomycin, wherein daptomycin is administered once every 24 hours.

10 17 The method according to claim 16, wherein the dose is 3 to 12 mg/kg.

18. The method according to claim 17, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

19. The method according to claim 16, wherein the dose is 10 to 25

20. The method according to claim 19, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

21. The method according to claim 17, wherein the dose is 25 to 75 mg/kg.

20                   22. The method according to claim 21, wherein the dose is 25, 50  
or 75 mg/kg.

23. The method according to claim 16, wherein said method reduces muscle toxicity compared to administration of daptomycin at a more frequent interval than 24 hours.

24. The method according to claim 18, wherein the dose is 4 mg/kg  
5 administered once every 24 hours.

25. The method according to claim 18, wherein the dose is 6 mg/kg administered once every 24 hours.

26. The method according to any one of claims 1, 6 or 16, wherein said administering is via oral, subcutaneous or intravenous administration.

10           27 A method for administering quinupristin/dalfopristin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.

15           28. The method according to claim 27, wherein quinupristin/dalfopristin is administered once every 24 hours to once weekly.

29. The method according to claim 28, wherein quinupristin/dalfopristin is administered once every 24 hours, 48 hours, 72 hours or 96 hours.

20           30. The method according to claim 27, wherein said quinupristin/dalfopristin is administered at a dose of 7.5 to 30 mg/kg.

31. The method according to claim 27, wherein said  
quinupristin/dalfopristin is administered at a dose of 7.5, 10, 12, 14, 16, 18, 20, 22,  
24, 26, 28 or 30 mg/kg.

5               32. A pharmaceutical composition comprising a single dose of  
daptomycin and a pharmaceutically acceptable carrier, wherein said single dose is 7  
to 15 mg/kg.

10              33. A pharmaceutical composition comprising a single dose of  
quinupristin/dalfopristin and a pharmaceutically acceptable carrier, wherein said  
single dose is 10 to 30 mg/kg.

10082544 022002